FDC gets 8 observation from USFDA for Waluj plant
New Delhi: Drug firm FDC has received establishment inspection report (EIR) from the US health regulator for its Waluj plant. The company said it had submitted a detailed compliance report to the US Food and Drug Administration (USFDA) within the stipulated period in response to the Form 483 containing eight observations issued to it by the regulator.
"The company has received an EIR for the said manufacturing facility, which was inspected from August 10, 2018, to August 16, 2018, by USFDA," FDC said in a statement.
The plant is considered to be acceptable with regards to current good manufacturing practices (GMPs) and the inspection stands closed, it added.
USFDA releases a copy of the EIR to the establishment that is subject of an FDA or FDA-contracted inspection when the agency determines the same to be closed.
EIREstablishment Inspection ReportFDCGMPgood manufacturing practicesUS Food and Drug AdministrationUSFDAWaluj plant
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd